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Background: The role of SFKs in G protein-coupled receptor-mediated platelet activation is not well understood.
Results: AYPGKF induced Gq/Ca2-dependent SFK phosphorylation, and AYPGKF-elicited platelet activation was partially
inhibited by PP2 but was completely abolished by PKC inhibitors plus SFK inhibitors.
Conclusion: Ca2/SFKs/PI3K and PKC represent alternative pathways mediating AYPGKF-dependent platelet activation.
Significance: This work increases understanding of important SFK functions in platelet activation.
The Src family kinases (SFKs) play essential roles in collagen-
and von Willebrand factor (VWF)-mediated platelet activation.
However, the roles of SFKs in G protein-coupled receptor-medi-
ated platelet activation and themolecularmechanisms whereby
SFKs are activated by G protein-coupled receptor stimulation
are not fully understood.Herewe show that the thrombin recep-
tor protease-activated receptor 4 agonist peptide AYPGKF elic-
ited SFK phosphorylation in P2Y12 deficient platelets but stim-
ulatedminimal SFKphosphorylation in platelets lackingGq.We
have previously shown that thrombin-induced SFK phosphory-
lation was inhibited by the calcium chelator 5,5-dimethyl-bis-
(o-aminophenoxy)ethane-N,N,N,N-tetraacetic acid (dimeth-
yl-BAPTA). The calcium ionophore A23187 induced SFK
phosphorylation in both wild-type and Gq deficient platelets.
Together, these results indicate that SFK phosphorylation in
response to thrombin receptor stimulation is downstream from
Gq/Ca2 signaling. Moreover, A23187-induced thromboxane
A2 synthesis, platelet aggregation, and secretion were inhibited
by preincubation of plateletswith a selective SFK inhibitor, PP2.
AYPGKF-induced thromboxane A2 production in wild-type
and P2Y12 deficient platelets was abolished by PP2, and
AYPGKF-mediated P-selectin expression, integrin IIb3 acti-
vation, and aggregation of P2Y12 deficient platelets were par-
tially inhibited by the PKC inhibitor Ro-31-8220, PP2, dimeth-
yl-BAPTA, or LY294002, but were abolished by Ro-31-8220
plus PP2, dimethyl-BAPTA, or LY294002. These data indicate
thatCa2/SFKs/PI3K andPKC represent two alternative signal-
ing pathways mediating Gq-dependent platelet activation.
The Src family of nonreceptor tyrosine kinases consists of
signaling enzymes that regulate cell growth, differentiation, cell
adhesion, carcinogesesis, and immune cell function (1). At least
six members of the Src family kinases (SFKs)3 are present in
platelets, including c-Src, Lyn, Fgr, Fyn, Lck, and Yes (2–4).
SFKs play distinct roles in various aspects of platelet activation.
c-Src binds to the cytoplasmic domain of the integrin subunit
3 and plays an important role in integrin IIb3-dependent
outside-in signaling (5–7). SFKs also play important roles in the
VWF/GPIb-IX-mediated platelet activation (8–11). The cyto-
plasmic domain of GPIb interacts with several intracellular
molecules including filamin, 14-3-3, SFKs (c-Src and Lyn), and
PI3K (12). SFKs appear to be upstream of PI3K and calcium
elevation in response to VWF (8). Among different SFK iso-
forms, the importance of Lyn (and to amuch less degree, c-Src)
has been shown in GPIb-IX signaling (11, 13). Lyn and Fyn,
which bind to the cytoplasmic domain of GPVI (14–16), have
been implicated in the GPVI-immunotyrosine-activating
motif-Syk signaling pathway. Therefore, activation of SFKs in
platelets by stimulation of the collagen receptor GPVI is a very
early signaling event. Upon cross-linking of GPVI, the immu-
notyrosine-activating motif of FcR -chain is tyrosine-phos-
phorylated by SFKs, leading to the activation of phospholipase
C (PLC) 2, the key effector enzyme in the GPVI signaling cas-
cade (17, 18). Activation of PLC 2 liberates the second mes-
sengers 1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphos-
phate, which results in PKC activation and calcium release,
respectively.
The role of SFKs in platelet activation induced by G protein-
coupled receptors is highly controversial. It has been reported
that selective inhibitors of SFKs have no effect, have a stimula-
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response to thrombin stimulation (19–22). Although an early
study reported that SFKs are not required in thrombin-induced
platelet aggregation (19), several other studies showed that
SFKs (mainly Lyn kinase) stimulate platelet activation and
secretion induced by thrombin (20, 21). However, a very recent
study reported that the SFK Fyn activated downstream of
G12/13 inhibits Gq-dependent intracellular calcium mobiliza-
tion, PKC activation, and thrombin-induced platelet aggrega-
tion (22). SFKs also play a role in Gi-dependent platelet activa-
tion and TXA2 synthesis (23, 24).
Platelets express many G proteins, including Gq, G12/13, Gi/z,
and Gs. G proteins are coupled to agonist receptors that stim-
ulate platelet activation, with the exception of Gs, which is cou-
pled to receptors for physiological platelet inhibitors (PGI2 and
adenosine) that mediate inhibitory signals by stimulating
adenylyl cyclase-dependent cAMP synthesis (25). The aim of
this study was to investigate the molecular mechanisms by
which SFKs were activated upon thrombin receptor stimula-
tion and to establish roles of SFKs in Gq-dependent platelet
activation. To accomplish this aim, we used a combination of
various knock-outmice, as well as pharmacological approaches
to dissect the signaling pathways mediating SFK phosphoryla-
tion and to examine the effects of selective SFK inhibitors on
platelet activation in response to thrombin receptor stimula-
tion.Wedemonstrate that activation of theGq/Ca2pathway is
sufficient to elicit SFK phosphorylation. Furthermore, we show
that Ca2/SFKs/PI3K synergizes with the PKC pathway to
mediate Gq-dependent platelet secretion and aggregation. In
addition, our data suggest that SFKs are direct effectors of Gi
and play important roles in ADP-induced platelet activation.
EXPERIMENTAL PROCEDURES
Materials—-Thrombin was purchased from Enzyme
Research Laboratories (South Bend, IN). PAR4 peptide
AYPGKF-NH2 and PAR1 peptide SFLLRN-NH2 were custom-
synthesized at Biomatik USA, LLC (Wilmington, DE). A cal-
pain inhibitor E64, ADP, Src inhibitor-1, and the P2Y1 antago-
nist MRS-2179 were from Sigma. Luciferase/luciferin reagent
and collagen were from Chrono-log (Havertown, PA). Forsko-
lin, Ro-31-8220, GÖ6983, PKC/ inhibitor, PP2, and
LY294002 were purchased fromCalbiochem. Calcium chelator
dimethyl-BAPTA, Fura-2/AM, and Pluronic F-127 were from
Invitrogen. Rabbit monoclonal antibodies against Lyn, the
phosphorylated Ser473 residue of Akt, and phosphorylated Src
at residues Tyr416 were from Cell Signaling Technology (Bev-
erly, MA). A mouse monoclonal antibody against Fyn, rabbit
polyclonal antibodies against Gi, and protein A/G beads were
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). cAMP
ELISA kit was from Amersham Biosciences. The TXB2 EIA kit
was from Assay Designs (Ann Arbor, MI). Oregon Green 488-
labeled fibrinogen was from Molecular Probes (Eugene, OR).
FITC-conjugated rat anti-mouseCD62P (P-Selectin)monoclo-
nal antibody was from BD Biosciences (San Diego, CA).
Animals—Mice deficient in Gq (26), P2Y12 (27), TP (28), and
Lyn (21, 29) were generated as described previously. Littermate
wild-type mice from heterozygous breeding were used as con-
trols. The mice were bred and maintained in the University of
Kentucky Animal Care Facility following institutional and
National Institutes of Health guidelines after approval by the
Animal Care Committee.
Preparation of Platelets—Blood was collected from the
abdominal aorta of isofluorane-anesthetized mice (8–10
weeks) using 1⁄7 volume of ACD (85 mM trisodium citrate, 83
mM dextrose, and 21 mM citric acid) as anticoagulant (30). For
each experiment, blood was pooled from three to four mice of
each genotype. The platelets were then washed twice with CGS
(0.12 M sodium chloride, 0.0129 M trisodium citrate, 0.03 M
D-glucose, pH 6.5). The platelets were resuspended in modified
Tyrode’s buffer (12 mM NaHCO3, 138 mM NaCl, 5.5 mM glu-
cose, 2.9 mM KCl, 2 mM MgCl2, 0.42 mM NaH2PO4, 10 mM
HEPES, pH 7.4) at 3  108/ml and incubated for 1 h at 22 °C
before use.
Platelet Aggregation and Secretion—Platelet aggregation at
37 °C was measured by detecting changes in light transmission
using a turbidometric platelet aggregometer (Chrono-Log)
with stirring (1000 rpm). ATP release was measured by adding
luciferin/luciferase reagent (3–12 l) to 250 l of a washed
platelet suspension 1 min before stimulation.
Western Blot Analysis of Akt and Src Phosphorylation—
Washed platelets were stimulated with agonists in a platelet
aggregometer at 37 °C for 5 min and then solubilized in SDS-
PAGE sample buffer. The platelets were preincubatedwith var-
ious inhibitors at the indicated concentrations or vehicle con-
trol at 37 °C for 5 min prior to the addition of the platelet
agonists to examine the effects of inhibitors on SFK phosphor-
ylation. Platelet or cell lysates were analyzed by SDS-PAGE on
4–15% gradient gels and immunoblotted using a polyclonal
anti-Akt antibody, rabbit monoclonal antibodies specific for
the phosphorylated Akt residue Ser473, or phosphorylated Src
residue Tyr416.
Ca2 Mobilization—Washed mouse platelets were incu-
bated with 12.5M Fura-2/AM, 0.2% Pluronic F-127 for 45min
at 37 °C. After washing with CGS, the platelets were resus-
pended to 3  108/ml in Tyrode’s solution. To determine the
role of SFKs in agonist-induced calcium mobilization, the
platelets were preincubated with Me2SO or PP2 (10 M) for 5
min prior to addition of agonists. Continuous fluorescent
measurements were analyzed by excitation at 340 and 380 nm,
and emission was measured at 509 nm using a model LS55
luminescence spectrometer (PerkinElmer Cetus, Waltham,
MA). The intracellular Ca2 level was expressed as relative flu-
orescence calculated based on the ratio of emissions simultane-
ously using FL WINLAB 4.0 software (PerkinElmer Cetus).
Rap1b Activation—The washed platelets were resuspended
in modified Tyrode’s solution were preincubated with Me2SO
or PP2 (10 M) for 5 min and then stimulated with agonists for
5 min at 37 °C in the aggregometer and lysed with the addition
of an equal volume of ice-cold lysis buffer (100 mM Tris,
400 mM NaCl, 5 mM MaCl2, 2% Nonidet P-40, 20% glycerol, 2
mM PMSF, 220 Kallikrein inhibitor unit/ml aprotinin, 1 mM
Na3VO4, 1g/ml leupeptin, pH 7.4). A sample containing 50l
of lysate was added with an equal volume of 2 SDS sample
buffer for the determination of total Rap1b levels. Active Rap1b
was precipitated by glutathione-linked agarose beads prebound
to RalGDS RBD fused to GST. Precipitated GTP-Rap1b was
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detected by SDS-PAGEand immunoblottingwith a rabbit poly-
clonal anti-Rap1b-specific antibody.
Measurement of TXA2—Washed platelets from wild-type or
P2Y12 deficient mice were stimulated with agonists for 5min at
37 °C in aggregometer and stopped by adding 10 mM EDTA
(final concentration). The platelet-free supernatant fraction
was diluted 1:50 with the assay buffer supplied in the TXB2 EIA
kit. TXB2, a stable metabolite of TXA2, was measured using the
manufacturer’s protocol. To determine the role of SFKs in ago-
nist-induced TXA2 production, platelets were preincubated
with PP2 for 5 min prior to addition of agonists.
P-selectin Expression—Washed platelets were stimulated
with AYPGKF for 5 min at 37 °C and fixed by adding parafor-
maldehyde. The platelets were then incubated with a FITC-
conjugated anti-mouse P-selectin antibody at 22 °C for 30 min.
P-selectin expression was analyzed by flow cytometer. The
platelets were preincubated with various inhibitors for 5 min
prior to the addition of AYPGKF to determine the role of PKC,
SFKs, and Ca2 in agonist-induced P-selectin expression.
Fibrinogen Binding Assay—Agonist-mediated integrin acti-
vation was examined by flow cytometry analysis of Oregon
Green 488-labeled fibrinogen binding to integrin IIb3.
Briefly, washed platelets were incubated with Oregon Green-
labeled fibrinogen and AYPGKF at 37 °C for 5 min in
aggregometer with stirring and stopped by adding 1% (final
concentration) paraformaldehyde. Fibrinogen binding was
analyzed by flow cytometry. The platelets were preincubated
with various inhibitors for 5min prior to the addition ofOregon
Green-labeled fibrinogen andAYPGKF to determine the role of
PKC, SFKs, PI3K, and Ca2 in agonist-induced integrin
activation.
Immunoprecipitation and Western Blotting—Washed plate-
lets were resuspended in modified Tyrode’s buffer at 1 
109/ml and solubilized by adding an equal volume of solubili-
zation buffer (2% Triton X-100, 0.1 M Tris, 0.01 M EGTA, and
0.15MNaCl, pH7.4) containing 0.2mME64, 2mMphenylmeth-
ylsulfonyl fluoride, and 220 Kallikrein inhibitor unit/ml apro-
tinin. After preclearedwith Sepharose 4B beads, 500l aliquots
of each platelet lysate were immunoprecipitated with the indi-
cated antibodies and protein A/G beads. Pulldown proteins
were analyzed by SDS-PAGE and immunoblotted using anti-
bodies against Gi, Lyn, or Fyn.
RESULTS
Activation of Gq-induced SFK Phosphorylation—Although
SFKs have been implicated in thrombin-induced platelet acti-
vation, it is unknownwhether or notGq signaling contributes to
SFK activation in response to thrombin receptor stimulation.
Thrombin activates mouse platelets via its receptor PAR4,
which does not couple directly to Gi. Thrombin-induced acti-
vation of Gi is secretion-dependent, mainly by secreted ADP
through its receptor P2Y12. SFK activity is correlated directly
with autophosphorylation and dephosphorylation of a tyrosine
residue in the middle of the catalytic domain (Tyr416 for c-Src).
Therefore, SFK activation can be detected by measuring the
extent of SFK autophosphorylation by Western blotting with a
rabbit monoclonal antibody that specifically recognizes the
phosphorylated SFK residue Tyr416. The PAR4 activator, the
peptide AYPGKF, elicited SFK phosphorylation in P2Y12 defi-
cient platelets (Fig. 1A). PKC is essential for platelet secretion.
Thus, platelets from P2Y12 deficient mice were preincubated
with a selective PKC inhibitor Ro-31-8220 to further exclude
the effect of secretion on AYPGKF-induced SFK phosphoryla-
tion. Treatment of P2Y12 deficient platelets with Ro-31-8220,
which abolished secretion from dense granules, did not affect
SFKphosphorylation (Fig. 1A). Thus, AYPGKF is able to induce
Gi-independent SFK activation. PAR4 couples toGq andG12/13.
We therefore usedGq deficientmice to determine the role ofGq
in AYPGKF-induced SFK activation. AYPGKF stimulated sub-
stantial SFK phosphorylation in wild-type platelets in the pres-
ence of Ro-31-8220 and/or the P2Y12 antagonist Cangrelor
(also named AR-C69931MX) but induced minimal SFK phos-
phorylation in platelets lackingGq (Fig. 1B). These results dem-
onstrate that AYPGKF-induced SFK phosphorylation is mainly
Gq-dependent. The serotonin receptor 5-HT2a only couples to
FIGURE 1. The Gq signaling and Ca
2 elicited SFK phosphorylation in
platelets. A, washed platelets from wild-type (P2Y12
/) and P2Y12 deficient
(P2Y12
/) mice were preincubated with Ro-31-8220 (RO) (5 M) or dimethyl
sulfoxide (DMSO) for 5 min and then stimulated with AYPGKF (500 M) at
37 °C for 5 min with stirring. SFK phosphorylation was detected by Western
blotting with a rabbit monoclonal antibody specifically recognizing the phos-
phorylated Src residue Tyr416. B, washed platelets from wild-type (Gq
/) and
Gq deficient (Gq
/) mice were preincubated with Me2SO, Cangrelor (1 M),
Ro-31-8220, or Cangrelor plus Ro-31-8220 for 5 min, and then stimulated with
AYPGKF (500 M) at 37 °C for 5 min with stirring. C, washed platelets from
C57B6 mice were preincubated with Me2SO, Cangrelor, or Ro-31-8220 for 5
min and then stimulated with serotonin (10 M) at 37 °C for 5 min with stir-
ring. D, washed platelets from TP deficient mice were stimulated with sero-
tonin at 37 °C for 5 min with stirring. E, washed platelets from wild-type
(Gq
/) and Gq deficient (Gq
/) mice were stimulated with A23187 (0.5 M)
at 37 °C for 5 min with stirring. F, washed platelets from TP deficient mice were
preincubated with buffer, MRS2179 (MRS) (10 M), Cangrelor, or MRS2179
plus Cangrelor for 5 min and then incubated with A23187 (0.5 M) or buffer at
37 °C for 5 min with stirring.
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Gq. Serotonin stimulated SFK phosphorylation in platelets
fromwild-typemice(Fig.1C).Serotonin-elicitedSFKphosphor-
ylation was neither inhibited by Cangrelor or Ro-31-8220 (Fig.
1C) nor affected by knock-out of the TXA2 receptor TP that
couples to G12/13 (Fig. 1D). Thus, serotonin-induced SFK phos-
phorylation is not dependent on Gi or G12/13 signaling.
Activation of SFKs by AYPGKF Was Downstream of Ca2
Signaling but Independent of CalDAG-GEF Signaling—Throm-
bin-induced phosphorylation of SFKs in P2Y12 deficient plate-
lets is inhibited by preincubation of platelets with the calcium
chelator dimethyl-BAPTA (31), suggesting that Gq-dependent
activation of SFKs is downstream of Ca2 signaling. To extend
these studies, we tested the ability of the calcium ionophore,
A23187, to induce SFK phosphorylation. A23187 indeed stim-
ulated SFK phosphorylation in platelets from wild-type and Gq
deficient mice, respectively (Fig. 1E). Stimulation of platelets
withA23187 causes ADP secretion andTXA2 synthesis. There-
fore, SFK phosphorylation induced byA23187was examined in
platelets lacking TP in the presence of ADP receptor antago-
nists to exclude the possibility that A23187-mediated SFK
phosphorylation is secondary to TXA2 and/or secreted ADP.
A23187 induced SFK phosphorylation in TP deficient platelets
in the presence of the ADP receptor antagonists Cangrelor plus
MRS-2179 (blocking P2Y1) (Fig. 1F).
Lyn kinase plays important roles in thrombin-induced plate-
let secretion and aggregation (20, 21). In agreement with the
role of Lyn kinase in thrombin-induced platelet activation,
A23187 (Fig. 2,A and B) and AYPGKF (Fig. 2,C andD), respec-
tively, induced SFK phosphorylation was diminished by Lyn
deficiency.
CalDAG-GEFI, which is downstream from Gq/Ca2 signal-
ing, plays an important role in PAR4-mediated Rap1 and IIb3
activation (32). To determine whether PAR4-mediated SFK
activation requires the CalDAG-GEFI signaling, AYPGKF-in-
duced SFK phosphorylation was examined in platelets lacking
CalDAG-GEFI. P2Y12 deficient mice were used to exclude
involvement of P2Y12/Gi signaling. AYPGKF elicited similar
levels of SFK phosphorylation in platelets fromCalDAG-GEFI/
P2Y12 double knock-out mice as that in P2Y12 deficient plate-
lets (Fig. 2E). AYPGKF-induced Rap1b activation in P2Y12 defi-
cient platelets was not affected by PP2 (Fig. 2F). Taken together,
activation of SFKs by PAR4 stimulation is independent of
CalDAG-GEFI signaling.
Activation of SFKs is an early signaling event for GPVI sig-
naling (17). Accordingly, collagen-elicited elevation of Ca2
was abolished by preincubation of plateletswith PP2 (Fig. 3). To
determine whether or not SFK signaling is involved in regulat-
ingGq-mediated PLC activation, the effect of PP2 on elevation
of Ca2 in response to AYPGKF was examined. Elevation of
Ca2 elicited by AYPGKF was not affected by preincubation of
platelets with PP2 (Fig. 3, A and C). Therefore, Gq-dependent
SFK activation is downstream, not upstream, of Ca2 signaling.
A23187-induced Platelet Activation and TXA2 Synthesis
Required SFKs—Next, the effect of PP2 on A23187-induced
platelet aggregation and secretion was examined to establish a
role of SFKs in Gq/Ca2-dependent platelet activation. Pre-
treatment of platelets with PP2 inhibited ATP release and
aggregation induced by low dose (100 nM) (Fig. 3D) but not
high dose (data not shown), A23187. Because low doseA23187-
induced aggregation and secretion were also attenuated in TP
deficient platelets (Fig. 3E), the effect of PP2 on A23187-in-
duced TXA2 production was examined to address whether
induction of TXA2 synthesis accounts for the stimulatory role
of SFKs in A23187-mediated platelet activation. A23187 elic-
ited less TXA2 production in P2Y12 deficient platelets than that
in wild-type platelets (Fig. 3F), indicating that A23187-stimu-
lated TXA2 synthesis through both P2Y12-dependent and -in-
dependentmechanisms. Pretreatment of P2Y12 deficient plate-
lets with PP2 abolished A23187-induced TXA2 production
(Fig. 3F). Similarly, AYPGKF-induced TXA2 production in
P2Y12 deficient platelets was abolished by PP2 treatment (Fig.
4A). Thus, Gq/Ca2-dependent TXA2 synthesis requires the
SFK signaling.
AYPGKF-induced Aggregation and Secretion Were Attenu-
ated by TP Deficiency—Aggregation and secretion in response
to low dose AYPGKF were reduced in TP deficient platelets
(Fig. 4B), identifying a role of TXA2 in low dose thrombin-
induced platelet activation. These results also suggest that
FIGURE 2. Lyn is one of the major SFK isoforms activated by Gq and
Gq-mediated SFK activation is independent of CalDAG-GEFI/Rap1b
signaling. A–D, washed platelets from wild-type (Lyn/) and Lyn deficient
(Lyn/) mice were preincubated with Cangrelor at 37 °C for 5 min, and then
stimulated with A23187 (A) or AYPGKF (C) for 5 min with stirring. Densitome-
try measurements from results in A and C were shown in B and D, respectively.
The values were normalized with respect to Lyn/ platelets in the absence of
agonists and Cangrelor and are expressed as relative phosphorylation
(means  S.D. from three separate experiments). Statistical significance was
determined using Student’s t test. *, p  0.01 versus Lyn/. E, washed plate-
lets from P2Y12 deficient (P2Y12
/) mice or P2Y12/CalDAG-GEFI double
knock-out mice (P2Y12
//CalDAG-GEFI/) were stimulated with AYPGKF at
37 °C for 5 min with stirring. SFK phosphorylation was detected by Western
blotting with a rabbit monoclonal antibody specifically recognizing the phos-
phorylated Src residue Tyr416. F, washed platelets from P2Y12 deficient mice
were preincubated with dimethyl sulfoxide (0.1%) or PP2 (10 M) and then
stimulated with AYPGKF (500 M) at 37 °C for 5 min with stirring. GTP-bound
Rap1 was precipitated with GST-RalGDS RBD bound to glutathione-agarose
beads.
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induction of TXA2 synthesis is one mechanism accounting for
the stimulatory role of SFKs in promoting platelet activation.
TheRole of SFKs in PAR4-dependent Platelet Aggregation and
Secretion—Although G12/13 signaling contributes to platelet
shape change (33), theGq signaling is responsible for thrombin-
induced Ca2 mobilization, secretion, and aggregation (26).
Secreted ADP, primarily by activating the Gi signaling via
P2Y12, contributes to PAR4-mediated platelet activation.
Therefore, P2Y12 deficient mice were used to exclude the effect
of the positive feedback mechanism and to establish a role of
SFKs in Gq-dependent platelet activation. Preincubation of
P2Y12 deficient platelets with PP2 inhibited aggregation and
ATP release in response to low dose AYPGKF (100 M) (Fig.
4C). However, aggregation and ATP release elicited by higher
doses (	250M) of AYPGKFwere only slightly reduced by PP2
treatment (Fig. 4C). These results suggest the existence of an
alternative pathway in Gq-dependent platelet activation under
those conditions. In support of this view, AYPGKF-induced
P-selectin expression (Fig. 5A) and integrin activation evident
as fibrinogen binding (Fig. 5B) were reduced but not abolished
by pretreatment of platelets with PP2 or dimethyl-BAPTA.
FIGURE 3. Effects of PP2 on AYPGKF-elicited Ca2 mobilization and
A23187-induced aggregation and TXA2 generation. A--C, washed plate-
lets from P2Y12 deficient platelets were labeled with 12.5 M Fura-2/AM, 0.2%
Pluronic F-127 and resuspended in Tyrode’s solution. A and B, platelets were then
preincubated with PP2 or dimethyl sulfoxide (DMSO) for 5 min and stimulated
with AYPGKF (500 M) (A) or collagen (5 g/ml) (B). C, changes in the intracellular
free calcium level were measured every 2 s and expressed as a ratio of fluores-
cence (FL) detected at 509-nm emission with excitation wavelengths of 340 and
380 nm. Summarized data from three experiments are shown. D, washed plate-
lets from C57BL/6 mice were preincubated with PP2 or dimethyl sulfoxide for 5
min and stimulated with A23187 (100 nM) in a lumi-aggregometer at 37 °C. Real
time ATP secretion and platelet aggregation were simultaneously recorded.
E, washed platelets from TP/ or TP/ mice were stimulated with A23187 in a
lumi-aggregometer at 37 °C. Real time ATP secretion and platelet aggregation
were simultaneously recorded. F, washed platelets from P2Y12 knock-out mice or
wild-type controls were preincubated with PP2 or dimethyl sulfoxide for 5 min
and stimulated with various concentrations of A23187 for 5 min at 37 °C with
stirring. The reactions were stopped by adding 10 mM of EDTA (final concentra-
tion). Because TXA2 has a half-life of 37 s and is rapidly converted to the stable
product TXB2, TXA2 was measured as TXB2 with TXB2 EIA kits. TXB2 production
data were obtained from three tests. Statistical differences were examined by
Student t test. The data are the means  S.D. *, p  0.001 versus dimethyl sulfox-
ide in the presence of same concentration of AYPGKF.
FIGURE 4. Effects of PP2 on AYPGKF-induced TXA2 synthesis and the
effects of TP deficiency and PP2 on AYPGKF-induced platelet aggrega-
tion and ATP secretion. A, washed platelets from P2Y12 knock-out mice or
wild-type controls were preincubated with PP2 or dimethyl sulfoxide (DMSO)
for 5 min and stimulated with various concentrations of AYPGKF (AY) for 5 min
at 37 °C with stirring. Statistical differences were examined by Student t test.
The data are the means  S.D. *, p  0.001 versus dimethyl sulfoxide in the
presence of same concentration of AYPGKF. B, washed platelets from TP/
or TP/ mice were stimulated with AYPGKF (40 M) in a lumi-aggregometer
at 37 °C. C, washed platelets from P2Y12 knock-out mice were preincubated
with PP2 or dimethyl sulfoxide for 5 min and stimulated with various concen-
trations of AYPGKF in a lumi-aggregometer at 37 °C. Real time ATP secretion
and platelet aggregation were simultaneously recorded.
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PKC is known to be important for Gq-dependent platelet
secretion and aggregation. Therefore, the effect of a non-iso-
form selective PKC inhibitor, Ro-31-8220, on AYPGKF-in-
duced aggregation of P2Y12 deficient platelets was examined to
confirm the role of PKC in Gq-mediated platelet activation.
Although preincubation of platelets with Ro-31-8220 abolished
AYPGKF-induced ATP release (Fig. 6A), Ro-31-8220 only par-
tially inhibited platelet aggregation in response to high concen-
trations of AYPGKF (	500 M). Aggregation of washed plate-
lets requires fibrinogen secreted from  granules and integrin
activation. In agreement with the results that Ro-31-8220 only
reduced aggregation, Ro-31-8220 inhibited but did not abolish
AYPGKF-induced secretion of P-selectin expression (Fig. 5A)
and fibrinogen binding (Fig. 5B). Based on these observations,
we hypothesize that the Ca2/SFK pathway and the PKC path-
way represent two parallel pathways mediating Gq-dependent
platelet activation. If this hypothesis is correct, AYPGKF-in-
duced integrin activation, aggregation, and secretion in P2Y12
deficient platelets should be abolished by a PKC inhibitor plus a
SFK inhibitor or dimethyl-BAPTA. Indeed, aggregation of
P2Y12 deficient platelets, even in response to high concentra-
tions of AYPGKF, was totally abolished by pretreatment of
platelets with Ro-31-8220 (5 M) plus dimethyl-BAPTA (10
M) orwith Ro-31-8220 plus PP2 (10M) (Fig. 6A). Ro-31-8220
at a lower concentration (1 M) achieved similar effect as 5 M
(data not shown). AYPGKF-induced P-selectin expression (Fig.
5A) and fibrinogen binding (Fig. 5B) were abolished by pre-
treatment of platelets with Ro-31-8220 plus PP2. AYPGKF-
elicited aggregation and secretion of P2Y12 deficient platelets
were also abolished by Ro-31-8220 plus another Src inhibitor,
FIGURE 5. Effects of PP2, Ro-31-8220, dimethyl-BAPTA, and LY294002 on AYPGKF-induced fibrinogen binding and P-selectin expression. A, washed
platelets from P2Y12 knock-out mice were preincubated with dimethyl sulfoxide (DMSO), PP2, Ro-31-8220, dimethyl-BAPTA (10 M) (BAPTA), Ro-31-8220 plus
PP2, or Ro-31-8220 plus dimethyl-BAPTA for 5 min and stimulated with AYPGKF (500 M) at 37 °C for 5 min with stirring and subsequently fixed with
paraformaldehyde. Fixed platelets were incubated with a FITC-labeled monoclonal anti-mouse P-selectin antibody for 30 min at 22 °C. Surface expression of
P-selectin was analyzed using flow cytometry. Data from a representative experiment and quantitative results from three experiments expressed as the mean
fluorescence index (mean fluorescence intensity of platelets stimulated with an agonist/fluorescence intensity of unstimulated platelets) are shown. The
statistical differences were examined by Student t test. The data are the means  S.D. *, p  0.005 versus dimethyl sulfoxide; #, p  0.05 versus resting platelets
(CON); , p  0.2 versus resting platelets. B, washed platelets from P2Y12 knock-out mice were preincubated with dimethyl sulfoxide, PP2, Ro-31-8220,
dimethyl-BAPTA, LY294002 (20 M) (LY), Ro-31-8220 plus PP2, Ro-31-8220 plus dimethyl-BAPTA, or Ro-31-8220 plus LY294002 for 5 min and stimulated with
AYPGKF (500 M) in the presence of FITC-labeled fibrinogen at 37 °C for 5 min with stirring and subsequently fixed with paraformaldehyde. Fibrinogen binding
was analyzed using flow cytometry. Data from a representative experiment and quantitative results from three experiments are expressed as the mean
fluorescence index (mean fluorescence intensity of platelets stimulated with an agonist/fluorescence intensity of unstimulated platelets) were shown. Statis-
tical differences were examined by Student t test. The data are the means  S.D. *, p  0.05 versus dimethyl sulfoxide; #, p  0.05 versus resting platelets
(CON); , p  0.2 versus resting platelets.
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the Src inhibitor 1 (Fig. 6B), or PP2 plus another pan-PKC
inhibitor, GÖ6983 (Fig. 6C). The novel PKC isoforms PKC 
and  have been implicated in PAR4/Gq-mediated platelet acti-
vation (34–37). A PKC/ specific inhibitor slightly inhibited
AYPGKF-induced platelet aggregation and secretion (Fig. 6D).
Although the PKC/ inhibitor plus PP2 markedly inhibited
platelet aggregation and secretion, they did not abolish platelet
aggregation and secretion elicited by AYPGKF. These results
indicate a role of the novel PKC isoforms in PAR4-induced
platelet activation but also suggest that other isoforms of PKC
are involved in PAR4-mediated platelet activation. Dimethyl-
BAPTAplus PP2 had no additive inhibitory effect onAYPGKF-
induced aggregation as compared with dimethyl-BAPTA or
PP2 alone (data not shown).
The Role of PI3K in PAR4-mediated Platelet Activation—We
have recently shown that activation of the PI3K/Akt pathway
elicited by Gq is downstream of Ca2/SFK signaling (31). Thus,
the effect of the PI3K inhibitor LY294002 onAYPGKF-induced
aggregation and secretion of P2Y12 deficient platelets was
examined to evaluate the role, if any, of SFKs in PI3K-mediated
platelet activation. As with dimethyl-BAPTA and PP2,
AYPGKF-elicited platelet aggregation and ATP release were
only partially inhibited by pretreatment of platelets with
LY294002 but were abolished by Ro-31-8220 plus LY294002
(Fig. 6A). Consistent with these results, fibrinogen binding to
IIb3 induced by AYPGKF was partially inhibited by preincu-
bation of platelets with LY294002 but was totally abolished by
Ro-31-8220 plus LY294002 (Fig. 5B).
The Role of SFKs in Gi-mediated Platelet Activation—It is
well established that the P2Y12/Gi pathway plays a key role in
agonist-induced activation of the PI3K/Akt pathway (31).
Although it is believed that P2Y12/Gi-dependent activation of
PI3K is mediated by the Gi  subunits (38), a previous study
showed that Gi-dependent Akt phosphorylation in human
platelets was inhibited by PP2 (39). Accordingly, ADP-induced
Akt phosphorylation in Gq deficient platelets was abolished by
preincubation of platelets with PP2 (Fig. 7A). These results sug-
gest that P2Y12/Gi-dependent activation of PI3K/Akt is down-
stream from the SFK signaling. Presumably, SFKs are direct
effectors of G proteins (40). Consistent with this view, Lyn (Fig.
7B) and Fyn (Fig. 7C) were pulled down from mouse platelet
lysates by a rabbit polyclonal antibody against Gi. Gi was pulled
down from mouse platelet lysates by antibodies against Lyn
(Fig. 7D) or Fyn (Fig. 7E). Thus, Lyn and Fyn interact with Gi in
platelets. ADP-induced SFK phosphorylation was significantly
attenuated in Lyn deficient platelets (Fig. 7F), indicating that
Lyn is one of themajor isoforms of SFKs that is activated by the
P2Y12/Gi pathway.
The Role of SFKs in PAR1-dependent Platelet Activation—
Thrombin activates human platelets mainly by the G protein-
coupled receptors PAR1 and PAR4. Thus, the role of SFKs in
PAR1-mediated platelet activation was investigated using the
PAR1 agonist peptide SFLLRN. As we expected, SFLLRN stim-
ulated SFK phosphorylation in washed human platelets (Fig.
7G). SFLLRN-induced SFK phosphorylation was inhibited by
dimethyl-BAPTA. In contrast, SFLLRN-induced Ca2 mobili-
zation was not affected by PP2 (Fig. 7H). These results indicate
that as with PAR4, PAR1-dependent SFK activation is down-
stream from Ca2 signaling. We examined the effect of PP2 on
SFLLRN-induced platelet aggregation andATP release to iden-
tify the role of SFKs in PAR1-mediated platelet activation.
Platelet aggregation in response to SFLLRNwas partially inhib-
ited by pretreatment of the platelets with PP2 or Ro-31-8220
but was abolished by PP2 plus Ro-31-8220 (Fig. 7I).
DISCUSSION
In this study, using a combination of knock-out mice and
pharmacological approaches, we documented and character-
ized the function of two alternative pathways for eliciting Gq-
dependent platelet secretion and aggregation. First, we discov-
ered that SFKs could be activated by the Gq/Ca2 pathway (Fig.
8). Our data indicate that Gq/Ca2-dependent SFK activation
plays an important role in AYPGKF-induced TXA2 synthesis.
We further demonstrate that PKC and Ca2/SFKs/PI3Ks rep-
resent two alternative pathways mediating Gq-dependent
secretion and aggregation. Additionally, we show that Lyn and
FIGURE 6. Effects of Src and PKC inhibitors, dimethyl-BAPTA, and
LY294002 on AYPGKF-elicited aggregation and ATP secretion of P2Y12
deficient platelets. A, washed platelets from P2Y12 knock-out mice were
preincubated with dimethyl sulfoxide (DMSO), PP2, Ro-31-8220, dimethyl-
BAPTA, LY294002, Ro-31-8220 plus PP2, Ro-31-8220 plus dimethyl-BAPTA, or
Ro-31-8220 plus LY294002 for 5 min and stimulated with 500 M of AYPGKF.
B, washed platelets from P2Y12 knock-out mice were preincubated with
dimethyl sulfoxide, Src inhibitor-1 (10 M), Ro-31-8220, or Ro-31-8220 plus Src
inhibitor-1 for 5 min and stimulated with 500 M of AYPGKF. C, washed plate-
lets from P2Y12 knock-out mice were preincubated with dimethyl sulfoxide,
PP2, GÖ6983 (2 M), or GÖ6983 plus PP2 for 5 min and stimulated with 500 M
of AYPGKF. D, washed platelets from P2Y12 knock-out mice were preincu-
bated with dimethyl sulfoxide, PP2, PKC/ inhibitor (2 M), or the PKC/
inhibitor plus PP2 for 5 min and stimulated with 500 M of AYPGKF.
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Fyn interact withGi, and SFK activation is important for P2Y12/
Gi-dependent Rap1b activation and platelet aggregation.
To our knowledge, this is the first documentation of the role
of Gq in thrombin receptor-dependent SFK activation. PAR4 is
a major thrombin receptor in mouse platelets, and PAR4 does
not couple directly to Gi (41). AYPGKF-induced activation of
the Gi pathway in mouse platelets depends mainly on ADP via
P2Y12 signaling. Therefore, AYPGKF elicited SFK phosphory-
lation in P2Y12 deficient platelets, even in the presence of the
PKC inhibitor Ro-31-8220, thereby abolishing platelet dense
granule secretion, demonstrating that AYPGKF is able to stim-
ulateGi-independent SFK activation. Although thrombin failed
to induce secretion and activation of Gq deficient platelets (26),
it is able to induce G12/13 activation leading to shape change
(33). Therefore, the data that AYPGKF elicited minimal SFK
phosphorylation in Gq deficient platelets indicate that PAR4-
mediated SFK phosphorylation is exclusively dependent on Gq
signaling.
The serotonin receptor 5-HTa2 only couples to Gq (42). We
show that serotonin induced SFK phosphorylation in the pres-
ence of Ro-31-8220 andCangrelor, respectively, and in TP defi-
cient platelets. Thus, it is unlikely that serotonin-induced SFK
phosphorylation is secondary to either the G12/13 pathway acti-
vated by TXA2 or to the Gi pathway activated by secreted ADP
or other dense granule contents. Together, our data demon-
strate unequivocally that activation of Gq is sufficient to acti-
vate SFKs. This conclusion does not exclude the possibility that
the G12/13 signaling might also contribute to the agonist-in-
duced SFK phosphorylation. We show that although AYPGKF
(Fig. 1B) or a TXA2 analog U46619 (data not shown) elicited
minimal SFK phosphorylation in Gq deficient platelets, they
potentiated ADP-induced SFK phosphorylation in Gq deficient
platelets (supplemental Fig. S1), suggesting a role of G12/13 in
SFK phosphorylation. A previous study reported that thrombin
could induce SFK phosphorylation in Gq deficient platelets
(39). However, in that study, thrombin-induced SFK phosphor-
ylation in Gq deficient platelets was not compared with wild-
type mouse platelets; therefore the absence of the appropriate
FIGURE 7. ADP- or SFLLRN-induced SFK phosphorylation and the roles of
SFKs in ADP- and SFLLRN-induced platelet activation. A, washed platelets
from Gq deficient (Gq
/) mice were preincubated with dimethyl sulfoxide
(DMSO) or PP2 and then stimulated with ADP (10 M) at 37 °C for 5 min with
stirring and solubilized with SDS-PAGE sample buffer. Phosphorylation of Akt
was detected by Western blotting with rabbit monoclonal antibodies specif-
ically recognizing the phosphorylated Akt residues Ser473. B and C, Lyn and
Fyn kinases were pulled down by an anti-Gi antibody. Washed platelets from
C57BL/6J mice were lysed, and the cell extracts were incubated with rabbit
IgG or a rabbit polyclonal antibody against Gi2 followed by incubation of
protein A/G beads. The immunoprecipitates were analyzed by Western blot-
ting with a rabbit polyclonal anti-Lyn antibody (B) or a mouse monoclonal
anti-Fyn antibody (C). D and E, Gi was pulled down by anti-Lyn or -Fyn anti-
bodies. Washed platelets from C57BL/6 mice were lysed, and the cell extracts
were incubated with mouse IgG, a mouse monoclonal antibody against Lyn
(D), or a mouse monoclonal antibody against Fyn (E) followed by incubation
of protein A/G beads. Immunoprecipitates were analyzed by Western blot-
ting with a rabbit polyclonal antibody against Gi. F, washed platelets from
wild-type (Lyn/) and Lyn deficient (Lyn/) mice were preincubated with
buffer or MRS-2179 for 5 min and then stimulated with ADP (10 M) at 37 °C
for 5 min with stirring. G, washed human platelets were preincubated with
dimethyl sulfoxide or dimethyl-BAPTA for 5 min and then stimulated with
SFLLRN (10 M) at 37 °C for 5 min with stirring. Src phosphorylation was
detected by Western blotting with a rabbit monoclonal antibody specifically
recognizing the phosphorylated Src residue Tyr416. H, washed human plate-
lets were labeled with 12.5 M Fura-2/AM, 0.2% Pluronic F-127 and resus-
pended in Tyrode’s solution. The platelets were then preincubated with PP2
or dimethyl sulfoxide for 5 min and stimulated with SFLLRN (10 M). Changes
in the intracellular free calcium level were measured every 2 s and expressed
as a ratio of fluorescence (FL) detected at 509-nm emission with an excitation
wavelength of 340 and 380 nm. I, washed human platelets were preincubated
with dimethyl sulfoxide, PP2, Ro-31-8220, or Ro-31-8220 plus PP2 for 5 min
and stimulated with 10 M of SFLLRN in a lumi-aggregometer at 37 °C. IB,
immunoblot; IP, immunoprecipitation.
FIGURE 8. Important roles of SFKs in G protein-coupled receptor-induced
platelet activation. Although the Gi pathway induces SFK activation by a
direct interaction, Gq coupling receptors such as PAR1 and PAR4 induce SFK
activation downstream from the PLC/Ca2 signaling. SFKs play important
roles in Gi- and Gq-dependent activation of the PI3K/Akt pathway, TXA2 syn-
thesis, platelet secretion, and activation. The Ca2/SFKs/PI3K pathway,
together with the DAG/PKC pathway, mediates Gq-dependent platelet
activation.
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control makes it difficult to evaluate the contribution of Gq in
thrombin-induced SFK phosphorylation.
SFKs are upstream of PLC activation upon GPVI stimula-
tion (17). In contrast, SFKs are not required for Gq-elicited
Ca2 elevation (Fig. 3). We conclude that Gq-dependent SFK
phosphorylation is downstream from Ca2. This conclusion is
supported by the results that AYPGKF-induced SFK phosphor-
ylation in P2Y12 deficient platelets is inhibited by dimethyl-
BAPTA (31). Our data are consistent with the findings that an
increase of Ca2 concentration can activate SFKs (43).
We next sought to establish a role of SFKs in Gq-mediated
platelet activation. Our results suggest that although platelet
activation in response to low dose AYPGKF requires SFK sig-
naling, there is an alternative pathwaymediatingGq-dependent
platelet activation in response to high-dose AYPGKF. Gq-me-
diated PLC activation results in generation of inositol 1,4,5-
trisphosphate and diacylglycerol, which promotesmobilization
of intracellular calciumand activation of PKC, respectively (44).
PKC is known to play a key role in Gq-dependent platelet secre-
tion and aggregation (34, 36, 45, 46). PKC-dependent platelet
activation requires its effector pleckstrin (47). AYPGKF at high
concentrations induces aggregation of PKC inhibitor-treated
platelets (Fig. 6), and thrombin can induce aggregation and
integrin activation of pleckstrin deficient platelets (47). These
data suggest a PKC-independent mechanism involved in
thrombin-induced platelet activation.
In this study, we show that platelet aggregation, integrin
IIb3 ligand binding function, and P-selectin expression in
response to high concentrations of AYPGKF peptide were par-
tially inhibited by the PKC inhibitors, the calcium chelator
dimethyl-BAPTA, or SFK inhibitors but were totally abolished
by a PKC inhibitor plus dimethyl-BAPTA or a SFK inhibitor.
Thus, we propose a new concept to explain Gq-mediated plate-
let activation that states PKC and Ca2/Src represent two par-
allel signaling pathways mediating Gq-dependent aggregation
and secretion from  granules (Fig. 8). Although both the PKC
pathway and the Ca2/SFK pathway are required for integrin
activation,  granule secretion, and platelet aggregation in
response to low dose of AYPGKF, each pathway is sufficient to
elicit aggregation in response to high concentrations of the
agonist.
Stimulation of platelets with AYPGKF induced TXA2 syn-
thesis, which appears to be important for low dose AYPGKF-
induced platelet aggregation and secretion. Our data suggest
that there are P2Y12-dependent and -independentmechanisms
responsible for PAR4-induced TXA2 synthesis. AYPGKF-in-
duced TXA2 production in P2Y12 deficient platelets was abol-
ished by PP2 treatment but not inhibited or even enhanced by
Ro-31-8220 treatment (data not shown). These data demon-
strate that the SFKpathway but not the PKCpathway is respon-
sible for PAR4-mediated TXA2 synthesis.
Identifying the roles of SFKs and PKC in PAR4-mediated
platelet activation does not exclude the possibility that throm-
bin-induced platelet activation may involve other signaling
pathways. In this regard, CalDAG-GEFI has been shown to play
a role in PAR4-mediated platelet activation (32). CalDAG-GEFI
plays a key role in agonist-induced Rap1b activation (32, 48).
We found that AYPGKF-induced Rap1b activation in P2Y12
deficient platelets is not affected by PP2 and that AYPGKF-
induced phosphorylation of SFKs was not inhibited by
CalDAG-GEFI deficiency (Fig. 2) (49). These results suggest
that Gq-mediated Rap1b activation is independent of the SFK
pathway (Fig. 8).
We reported recently that the Gq-dependent activation of
the PI3K/Akt pathway requires the Ca2/SFKs pathway, but
not the PKC pathway (31). Similar to dimethyl-BAPTA and
PP2, the PI3K inhibitor LY294002 partially inhibited AYPGKF-
induced secretion and aggregation in P2Y12 deficient platelets.
Aggregation of and secretion by P2Y12 deficient platelets were
completely abolished by treatment with Ro-31-8220 plus
LY294002. These findings are consistent with the previous
report that the PI3K inhibitor LY294002 inhibited thrombin-
induced aggregation of pleckstrin-null platelets (47). PAR4
forms homodimers in platelets, which is important for PAR4
signaling (50). PAR4 can also form heterodimers with P2Y12 in
thrombin-stimulated platelets (51). Although the role of SFKs
in the formation of PAR4 homodimer or heterodimer with
P2Y12 is unclear, Lyn kinase, but not other SFK kinases, associ-
ates with arrestin-2 and PI3K / subunits in thrombin-stim-
ulated platelets that may be important for thrombin-induced
Akt phosphorylation (51). These data are consistent with the
findings that Lyn is one of the major SFK isoforms that is acti-
vated by the Gq/Ca2 signaling (Fig. 2) and that Lyn plays a role
in thrombin-elicited Akt phosphorylation (20).
We conclude that SFKs can be activated by the Gi pathway in
platelets. This conclusion is supported by the data demonstrat-
ing that 1) ADP-elicited SFK phosphorylation in wild-type
platelets is abolished by a P2Y12 antagonist but not by a P2Y1
antagonist and 2) ADP stimulated SFK phosphorylation in Gq
deficient but not in P2Y12 deficient platelets (supplemental Fig.
S1). This conclusion is consistent with a previous report show-
ing that either Gi or Gz signaling is sufficient to activate SFKs
(24). We show that Lyn and Fyn interact with Gi in platelets,
suggesting that SFKs are direct effectors of Gi in platelets.
Platelets express both type IA (PI3K and PI3K) and IB
(PI3K) classes of PI3K (52). PI3K is a major isoform of PI3Ks
that is activated by Gi (38). PI3K can be activated by G
subunits of heterotrimeric G proteins in vitro; therefore it has
been suggested that PI3K relays signals from G protein-cou-
pled receptors (53–55). Akt phosphorylation by Gi stimulation
depends on the PI3K signaling (30). Our data show that phos-
phorylation of Akt in response to ADP stimulation of Gq defi-
cient platelets or in wild-type platelets in the presence of a P2Y1
antagonist is inhibited by PP2, indicating that Gi-dependent
PI3K/Akt activation is likely to be downstream from SFKs but
not directly byG subunits. Our data show that ADP-induced
fibrinogen binding, Rap1b activation, and aggregation were
inhibited by PP2 (supplemental Fig. S2, A–C), suggesting
important roles of SFKs in Gi-dependent platelet activation.
However, preincubation of platelets with PP2 did not affect
ADP-induced inhibition of cAMP production in forskolin-
stimulated platelets (supplemental Fig. S2D) (56), suggesting
that SFKs are not involved in ADP inhibition of adenylate
cyclase.
In conclusion, Fig. 8 summarizes the findings that thrombin
activates SFKs through the Ca2 signaling that synergizes with
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the PKC pathway to mediate Gq-dependent platelet secretion
and activation. Platelet activation includes a series of rapid pos-
itive feedback loops that greatly amplify activation signals and
enable robust platelet recruitment and stabilization of thrombi
at the site of vascular injury. Two important mechanisms for
amplification are the secretion of granule contents (mainly
ADP) and synthesis of TXA2 from cyclooxygenase 1 signaling.
SFKs are required for PAR4-mediatedTXA2 synthesis, whereas
PKC is required for cargo release fromdense granules including
ADP. Our data also suggest that the SFK and PKC pathways are
mutually compensatory for integrin activation and  granule
release in response to PAR4 stimulation. Additionally, our data
demonstrate that SFKs are direct effectors ofGi andplay impor-
tant roles in Gi-dependent activation of the PI3K/Akt pathway
in platelets.
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